БИБЛИОТЕКА
-
- Фильтр
- Количество записей: 3194
-
- По дате
- По просмотрам
-
Зарубежные материалы
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientifc evidence from across the world in 2007–2017
Te International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM). People with diabetes comprise 8.8% of the world’s population, and IDF predicts that the number of cases of diabetes will rise to 642 million by 2040
Подробнее858
-
Статьи
Алгоритмы специализированной медицинской помощи больным сахарным диабетом (8-й выпуск)
Данное издание содержит девятый актуализированный выпуск (дополненный) клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.
Подробнее909
-
Зарубежные материалы
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes.
Подробнее814
-
Зарубежные материалы
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (The new england journal of medicine)
The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.
Подробнее648
-
Статьи
Инициация терапии сахарного диабета 2 типа: новые возможности
В настоящее время сахарный диабет (СД) 2 типа является глобальной проблемой здравоохранения – распространенность патологии достигла масштабов эпидемии как в развитых, так и развивающихся странах
Подробнее740
-
Зарубежные материалы
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.
Подробнее638
-
Зарубежные материалы
Cardiorenal Syndrome
The term cardiorenal syndrome (CRS) increasingly has been used without a consistent or well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of heartkidney interactions, we present a new classification of the CRS with 5 subtypes that reflect the pathophysiology, the time-frame, and the nature of concomitant cardiac and renal dysfun ...
Подробнее826
-
Зарубежные материалы
2018 ESC/ESH Guidelines for the management of arterial hypertension
The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)
Подробнее791
-
Зарубежные материалы
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Подробнее831
-
Статьи
Артериальная гипертензия у взрослых
Артериальная гипертензия (АГ) — синдром повышения клинического артериального давления (АД) при гипертонической болезни и симптоматических АГ выше пороговых значений, определенных в результате эпидемиологических и рандомизированных контролируемых исследований, продемонстрировавших связь с повышением сердечнососудистого риска и целесообразность и пользу лечения, направленного на снижение АД ниже ...
Подробнее1072
-
Зарубежные материалы
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Abstract—The American Heart Association (AHA) and the American Diabetes Association (ADA) have each published guidelines for cardiovascular disease prevention: The ADA has issued separate recommendations for each of the cardiovascular risk factors in patients with diabetes, and the AHA has shaped primary and secondary guidelines that extend to patients with diabetes. This statement will attempt to ...
Подробнее792
-
Зарубежные материалы
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology(ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).
Подробнее643
-
Зарубежные материалы
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...
Подробнее799
-
Зарубежные материалы
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Подробнее992
-
Зарубежные материалы
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and theEuropeanAssociation for the Study of Diabetes (EASD)
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education ...
Подробнее737
- ← Предыдущая
- 1
- ...
- 82
- 83
- 84
- 85 (current)
- 86
- 87
- 88
- ...
- 213
- Следующая →